Glox Therapeutics secures £500K from a £3M fund to develop antibiotics targeting antimicrobial-resistant lung infections in ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...

A novel once-daily drug showed a comparable efficacy and safety profile as the standard-of-care drug in patients with cystic ...

Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally ...

When cystic fibrosis hits your lungs hard, hit back. Everything you need to know about getting your lungs back into shape is ...

Sophie would make a world record for being the first man or woman with cystic fibrosis to row across the Atlantic, while at ...

"Glox to develop precision antibiotics for cystic fibrosis" was originally created and published by Pharmaceutical Technology ...

Children whose cystic fibrosis is caused by a rare gene variant are excluded from a new treatment which could potentially ...

K grant to accelerate development of Glox Therapeutics' novel precision antibiotics targeting AMR lung infections in people ...

The commitment of organizations like the Cystic Fibrosis Foundation to global research funding and access initiatives has further propelled market growth. Additionally, major pharmaceutical companies, ...